Close
Nordic 9Nordic 9

Gemma Frisius Fund (investor - Venture Capital)

Belgium lrd.kuleuven.be
See something wrong or missing? Let us know
Offices:Leuven

Gemma Frisius Fund (GFF) is a seed capital fund, established in 1997 as a joint venture between KU Leuven, KBC Group and BNP Paribas Group.

Average round investment:20.77M USD
Average number per year:1.2
Distribution: 2025 (1)2024 (1)2023 (1)2022 (2)2021 (1) See the entire list
Portfolio companies: Belgium Augustine TherapeuticsBelgium DualyxBelgium MyCellHub See the entire list
Mostly invests in: Belgium Belgium (10) Biotech (8)
See the entire list

Showing 3 of 10 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Gemma Frisius Fund mostly invests with:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Gemma Frisius Fund

Name Criteria
Belgium TheClubDeal
83%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Biotech, Manufacturing, Health services, Pharma, Software Services
  • Similar business models: B2B
  • Common investees countries: Belgium
  • Average number of deals per year: 1.2
  • Active last 12 months: Yes
United Kingdom Isomer Capital
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Manufacturing, Health services, Software Services
  • Similar business models: B2B
  • Common investees countries: Belgium
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
China China Grand Pharmaceutical and Healthcare Holdings
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Belgium
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
Belgium Invest Mons Borinage Centre
83%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Biotech, Manufacturing, Agriculture, Software Services
  • Similar business models: B2B
  • Common investees countries: Belgium
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Charcot-Marie-Tooth Research Foundation
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Manufacturing, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Belgium
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Global Emerging Markets
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Manufacturing, Health services, Pharma, Software Services
  • Similar business models: B2B
  • Common investees countries: Belgium
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
Switzerland MTIP AG
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Manufacturing, Health services, Pharma, Software Services
  • Similar business models: B2B
  • Common investees countries: Belgium
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
Luxembourg New Space Capital
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Manufacturing, Software Services, Hardware
  • Similar business models: B2B
  • Common investees countries: Belgium
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
Belgium BNP Paribas Fortis Private Equity
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Manufacturing, Health services, Pharma, Agriculture, Software Services, Hardware
  • Similar business models: B2B
  • Common investees countries: Belgium
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
France CPH Banque
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Manufacturing, Health services
  • Similar business models: B2B
  • Common investees countries: Belgium
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
Top